Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:21:38.178Z.
Calculation as of: 2026-10-06T19:21:38.178Z.
Quote observation: 2026-10-06T19:20:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
PE RATIO
N/A
Market Cap
$125.16M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $120.92M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $120.22M | N/A | N/A | N/A | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A | N/A | N/A | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.83M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.37M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.46M | N/A | N/A | N/A | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.16M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.18M | N/A | 2.13 | 2.46 | 2.46 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.80
Forward EPS (Est.)
$-1.81
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
